$heff's $tation of $tocks & $olid DD

[RKInvHub]

EYEG Upcoming EGP-437 P3 trial results

I have been a long time lurker and wanted to see if I could contribute to the collective wisdom, as well as seek advise on stocks I own/ want to buy.

EYEG seems to successfully pass the 1st Phase 3 trial (seems to be a non-inferior trial). Expected to report results from the 2nd phase 3 before the qtr end. Need to be re-confirmed as in the recent updates, they are rewarding/ stating that EGP-437 NDA submission year-end 2017

Partnered with Valeant Pharmaceuticals (Bausch & Lomb)

Eyegate Corporate Presentation

Q1 Financial Results, Operating Update

"On the operational front, the company continues to make progress with its EGP-437 clinical programs as well as with CMHA-S, Jade’s cross-linked hyaluronic acid compound. Near-term timelines for the three EGP-437 clinical trials remain unchanged, specifically that EYEG expects top-line data from the anterior uveitis phase III study in Q1 2017 and in Q2 of this year to have top-line data from both the second leg of the phase Ia/IIb macular edema trial as well as from the phase Ia/IIb post-cataract surgery study. "

Any thoughts?